> INVERSTORS & NEWS
ISU Abxis announced
that the first patient has been dosed in a Phase 1 Part 2 clinical trial of ISU104,
a monoclonal antibody blocking ErbB3 activation.
The Phase 1
Part 2 clinical study will be conducted at five Korean clinical sites(Asan Medical
Center, Seoul National University Hospital, Samsung Medical Center, Kosin
University Gospel Hospital, and Kyungpook National University Chilgok Hospital)
with 18 patients with recurrent and/or metastatic head and neck squamous
cell carcinoma(HNSCC; excluding nasopharyngeal
The Part 2 study
is a study that evaluating safety, efficacy, tolerability
and pharmacokinetic of ISU104 in mono and combination therapy with cetuximab in
patients with recurrent/metastatic HNSCC. The Phase 1 Part 2 study is planned
to be done by next year.
ISU Abxis have announced that they presented positive interim
results for a Phase 1 Part 1 clinical trial of ISU104 at the European Society
of Medical Oncology (ESMO) 2019 Annual Congress.
ISU104 is a
monoclonal human antibody targeting ErBb3 that inhibits tumor growth and
resistance to the current standard cancer treatments as blocking
ligand-dependent ErbB3 activation and inhibiting dimerization of ErbB3 with
ErbB1 or ErbB2.